Pharmacodynamic Model of Hepcidin Regulation of Iron Homeostasis in Cynomolgus Monkeys

被引:7
作者
Krzyzanski, Wojciech [1 ]
Xiao, Jim J. [2 ,3 ]
Sasu, Barbra [4 ,5 ]
Hinkle, Beth [6 ]
Perez-Ruixo, Juan Jose [2 ,7 ]
机构
[1] Univ Buffalo, Dept Pharmaceut Sci, Buffalo, NY USA
[2] Amgen Inc, Pharmacokinet & Drug Metab, Thousand Oaks, CA 91320 USA
[3] Clovis Oncol, Clin Pharmacol, San Francisco, CA USA
[4] Amgen Inc, Oncol, Thousand Oaks, CA 91320 USA
[5] Pfizer, Res Oncol, San Francisco, CA USA
[6] Amgen Inc, Comparat Biol & Safety Sci, Thousand Oaks, CA 91320 USA
[7] Janssen Res & Dev, Beerse, Belgium
关键词
ferrokinetics; hepcidin; iron kinetics; iron-restricted erythropoiesis; RECOMBINANT-HUMAN-ERYTHROPOIETIN; HEALTHY-SUBJECTS; MEDICAL PROGRESS; CHRONIC DISEASE; METABOLISM; PHARMACOKINETICS; HUMANS; FERROKINETICS; INFLAMMATION; KINETICS;
D O I
10.1208/s12248-016-9886-1
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Hepcidin (H-25) is a hormone peptide synthesized by the liver that binds to ferroportin and blocks iron export. In this study, H-25 was inhibited by administration of single and multiple doses of an anti-H-25 monoclonal antibody Ab 12B9m in cynomolgus monkeys. The objective of this analysis was to develop a pharmacodynamic model describing the role of H-25 in regulating iron homeostasis and the impact of hepcidin inhibition by Ab 12B9m. Total serum H-25 and Ab 12B9m were determined in each animal. Corresponding measurements of serum iron and hemoglobin (Hb) were obtained. The PD model consisted of iron pools in serum (Fe-S), reticuloendothelial macrophages (Fe-M), hemoglobin (Fe-Hb), and liver (Fe-L). The iron was assumed to be transported between the Fe-S, Fe-Hb, and Fe-M unidirectionally at rates k (S), k (Hb), and k (M). H-25 serum concentrations were described by the previously developed PK model with the parameters fixed at their estimates. The serum iron and Hb data were fitted simultaneously. The corresponding estimates of the rate constants were k (S)/Fe-0 = 0.113 h(-1), k (M) = 0.00191 h(-1), and k (Hb) = 0.00817 h(-1). The model-based IC50 value for the H-25 inhibitory effect on ferroportin activity was 0.398 nM. The PD model predicted a negligible effect of Ab 12B9m on Hb levels for the tested doses. The presented PD model adequately described the serum iron time courses following single and multiple doses of Ab 12B9m. Ab 12B9m-induced inhibition of H-25 resulted in a temporal increase in serum and liver iron and a decrease in the iron stored in reticuloendothelial macrophages.
引用
收藏
页码:713 / 727
页数:15
相关论文
共 33 条
[11]   Molecular control of iron transport [J].
Ganz, Tomas .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2007, 18 (02) :394-400
[12]   Iron dosing in kidney disease: inconsistency of evidence and clinical practice [J].
Gaweda, Adam E. ;
Ginzburg, Yelena Z. ;
Chait, Yossi ;
Germain, Michael J. ;
Aronoff, George R. ;
Rachmilewitz, Eliezer .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2015, 30 (02) :187-196
[13]   Regulation of monocytes and macrophages cell fate [J].
Gonzalez-Mejia, M. Elba ;
Doseff, Andrea I. .
FRONTIERS IN BIOSCIENCE-LANDMARK, 2009, 14 :2413-2431
[14]   Detection, evaluation, and management of iron-restricted erythropoiesis [J].
Goodnough, Lawrence Tim ;
Nemeth, Elizabeta ;
Ganz, Tomas .
BLOOD, 2010, 116 (23) :4754-4761
[15]   BLOOD FERROKINETICS IN NORMAL MAN [J].
HOSAIN, F ;
MARSAGLI.G ;
FINCH, CA .
JOURNAL OF CLINICAL INVESTIGATION, 1967, 46 (01) :1-&
[16]   Pharmacokinetics and Pharmacodynamics of the Erythropoietin Mimetibody™ Construct CNTO 528 in Healthy Subjects [J].
Jose Perez-Ruixo, Juan ;
Krzyzanski, Wojciech ;
Bouman-Thio, Esther ;
Miller, Bruce ;
Jang, Haishan ;
Bai, Stephen A. ;
Zhou, Honghui ;
Yohrling, Jennifer ;
Cohen, Adam ;
Burggraaf, Jacobus ;
Franson, Kari ;
Davis, Hugh M. .
CLINICAL PHARMACOKINETICS, 2009, 48 (09) :601-613
[17]   Time-course analysis of hepcidin, serum iron, and plasma cytokine levels in humans injected with LPS [J].
Kemna, E ;
Pickkers, P ;
Nemeth, E ;
van der Hoeven, H ;
Swinkels, D .
BLOOD, 2005, 106 (05) :1864-1866
[18]   Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after multiple subcutaneous doses in healthy subjects [J].
Krzyzanski, W ;
Jusko, WJ ;
Wacholtz, MC ;
Minton, N ;
Cheung, WK .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2005, 26 (3-4) :295-306
[19]  
LANDAW SA, 1988, BLOOD CELLS, V14, P47
[20]   Systems analysis of iron metabolism: the network of iron pools and fluxes [J].
Lopes, Tiago J. S. ;
Luganskaja, Tatyana ;
Spasic, Maja Vujic ;
Hentze, Matthias W. ;
Muckenthaler, Martina U. ;
Schuemann, Klaus ;
Reich, Jens G. .
BMC SYSTEMS BIOLOGY, 2010, 4